Browse the evidence

Creatine supplementation does not significantly affect fat mass (FM), BMI, or body fat percentage (BFP) in the general population, although specific loading protocols with maintenance phases may lead to modest BFP reductions.

Do not take creatine expecting it to burn fat or change your body fat percentage. It will not significantly affect your fat mass or BMI. Its primary benefit is adding lean muscle mass when combined with resistance training.

Treatment persistence was high, with 80% of patients completing 6 months of therapy.

High treatment persistence suggests that patients are likely to continue tirzepatide therapy.

Gastrointestinal adverse events were the most frequently reported but rarely led to treatment discontinuation.

Practitioners should monitor for gastrointestinal side effects but can expect them to be manageable.

Subgroup analyses did not suggest differences in outcomes based on diabetes status or GLP-1 receptor agonist used.

GLP-1 RAs can be considered safe for use in diverse patient populations without increased risk of suicidality.

The estimated health care cost offsets from clinical benefits of GLP-1RAs are projected to be $18.2 billion over 10 years.

Practitioners should consider the potential health care savings from clinical benefits of GLP-1RAs.

Treatment with semaglutide was associated with a significant odds of NAION (OR, 3.92; 95% CI, 1.02-15.02).

Clinicians should monitor for NAION in patients treated with semaglutide.

Current evidence remains insufficient to establish definitive conclusions regarding the association of semaglutide with NAION.

Further research is needed to clarify the risk of NAION with semaglutide.

The screening criteria for sarcopenic obesity include BMI, waist circumference, calf circumference, the SARC-F, and the Finger Ring test.

These criteria can guide practitioners in screening for sarcopenic obesity.

Gender, household size, and education were associated with GLP-1 use and interest.

Marketers should consider demographic factors when targeting potential GLP-1 consumers.

Persistence in the OMM-eligible cohort was 73.8%.

High persistence rates suggest good adherence to tirzepatide among eligible patients.

Real-world evidence suggests slower tirzepatide dose escalation than in clinical trials.

Practitioners may need to adjust expectations regarding dose escalation in real-world settings.

Obesity is projected to affect approximately half the US population by the year 2035.

Practitioners should be aware of the increasing prevalence of obesity for public health planning.

Human body weight is physiologically regulated and maintained within a relatively narrow range in most mammals, including humans.

Understanding body weight regulation can inform strategies for managing obesity.

Difficulties in achieving body weight loss and maintenance in obese subjects are partly due to physiological regulatory systems that resist weight loss.

Recognizing these physiological challenges can guide effective weight loss strategies.

Obesity is a global epidemic and a significant public health challenge.

Recognize obesity as a critical issue in public health.

Current anti-obesity medications (AOMs) include gastrointestinal lipase inhibitors, nutrient-stimulated hormone-based therapies, and emerging multi-receptor agonists.

Consider these AOMs in obesity treatment strategies.

The prevalence of obesity among youth with type 1 diabetes increased from 18.1% to 26.0% from 2008-2011 to 2020-2023.

Healthcare providers should be aware of the rising obesity rates in youth with T1D for better management strategies.

The prevalence of obesity among adults with type 1 diabetes rose from 30.5% to 38.1% from 2008-2011 to 2020-2023.

Healthcare providers should recognize the increasing obesity rates in adults with T1D for effective treatment planning.

A new sub-specialty, Cardiovascular-Endocrine-Metabolic Medicine, is proposed to unify care across multiple specialties.

Healthcare systems should consider integrating this new sub-specialty for improved patient outcomes.

By the fifth month, nearly one-half (46%) of semaglutide users had discontinued the treatment.

Practitioners should be aware of the high discontinuation rates when prescribing semaglutide.

Higher discontinuation rates were associated with lower household income and education level.

Socioeconomic factors should be considered when evaluating patient adherence to semaglutide.

Therapy was stopped in 2 patients, both of whom had resolution of symptoms.

Stopping semaglutide may resolve allodynia symptoms in affected patients.

Two patients opted to continue semaglutide despite the adverse effect, with one experiencing resolution after 4 months.

Some patients may choose to continue semaglutide, and symptom resolution can occur over time.

Current anti-obesity drugs have limitations regarding efficacy, side effects, weight regain, and high costs.

Awareness of these limitations can guide practitioners in seeking innovative treatment options.